By Robert Zott, Director of Advisory Services Development
Originally published March 27, 2018
It’s easy to read Europe’s Clinical Evaluation Guidance Document MEDDEV 2.7/1 Revision 4 (referred to as “Rev. 4”) and come away with the impression that clinical data—whether in the form of investigations carried out by the manufacturer of a medical device or published literature on the subject device or an equivalent—is required in order to meet the guidance.
While clinical data is required for manufacturers of high risk devices and implants, the vast majority of manufacturers that make low-to-medium risk devices may not need to conduct clinical trials for their products or produce peer-reviewed literature that supports their clinical use.
This article helps identify the specific clauses of the guidance document and regulations that pertain to clinical data and explores alternative pathways to compliance.
Access the article here.
Get Our Free Article
Simply fill in the form below, verify your email address
and you’ll be sent a link to download our free article.
Related Posts
- 56By Erica Kramer, Ph.D., Nerac Analyst Originally Published: November 14, 2017 The global in vitro diagnostics (IVD) market was worth about $61.1 billion in 2016 and is projected to grow to $84.6 billion by 2023, with Europe accounting for the second largest market share after North America. The expected market growth, and increased interest in…
- 55By Ron Sills, Nerac Analyst, and Donna Mitchell-Magaldi, Nerac Analyst Originally Published: September 26th, 2014 In 2009, the European Commission released MedDev 2.7.1 Rev.3 “Clinical Evaluation: A Guide for Manufacturers and Notified Bodies” as a supplement to the requirements of the EU Medical Device Directive 93/42/EEC. In order for medical devices to be marketed in…
- 55By Robert Zott, Sr. Regulatory Analyst Originally Published: November 14, 2017 The publication of the new Medical Device Regulation (MDR) 2017/745 in the European Journal, with its entry into force on May 25, 2017, marks the end of an eight-year period of controversy, and the beginning of a three-year transition to the most sweeping regulatory…